An Act to Require Health Insurance Carriers to Provide Coverage for Blood Testing for Perfluoroalkyl and Polyfluoroalkyl Substances
Maine Legislature, Session 131, LD 0132
Committee Amendment CA_A_SA_A_S734 (Senate)

SENATE AMENDMENT "I/ "to COMMITTEE AMENDMENT "A" to S.P. 71, 
L.D. 132, "An Act to Require Health Insurance Carriers to Provide Coverage for Blood 
Testing for Perfluoroalkyl and Polyfluoroalkyl Substances" 
Amend the amendment by insetting after section 1 the following: 
'Sec. 2. No addition to State's essential health benefits; legislative finding. 
The Legislature finds that the requirements of this Act do not constitute an addition to th~ 
State's essential health benefits that requires defrayal of costs by the State pursuant to 42 
United States Code, Section 18031(d)(3)(B) because this Act requires coverage for blood 
testing for perfluoroalkyl and polyfluoroalkyl substances, or PF AS, that is recommended 
by a provider as medically necessary health care upon a provider's determination that the 
clinical guidelines for blood testing for PF AS established by the National Academies of 
Sciences, Engineering, and Medicine, its successor organization or a comparable 
organization have been met.' 
Amend the amendment by striking out all of section 3. 
Amend the amendment by relettering or renumbering any nonconsecutive Part letter or 
section number to read consecutively. 
SUMMARY 
This amendment adds language stating the Legislature's finding that the requirements 
for coverage of blood testing for perfluoroalkyl and polyfluoroalkyl substances, or PF AS, 
are not an addition to the State's essential health benefits that would require the State to 
defray costs pursuant to the federal Patient Protection and Affordable Care Act. The 
amendment also strikes the appropriations and allocations section. 
SPONSORED BY: __ 
lM._, -~-b.___....;:.,.~...;:;__---
(Senator ROTUNDO, M.) 
COUNTY: Androscoggin 
FISCAL NOTE REQUIRED·_ 
(See attached) 
Page I - 131LR0143(04) 
SENATE AMENDMENT 
Approved: 04/24/24 feae 
LD 132 
LR 143(04) 
An Act to Require Health Insurance Carriers to Provide Coverage for Blood Testing for 
Perfluoroalkyl and Polyfluoroalkyl Substances 
Fiscal Note for Senate Amendment 'fl" to Committee Amendment "A" {5~73ij'i 
Sponsor: Sen. Rotundo of Androscoggin 
'/ 
Net c;ost (Sav_ings) 
General Fund .. 
Highway Fund 
Appropriations/Allocations 
General Fund 
Highway Fund 
Fiscal Detail and Notes 
Fiscal Note Required: Yes 
Fiscal Note 
FY 2023-24 
$0 
$0 
$0 
$0 
FY 2024-25 
($90,000) 
$0 
($90,000) 
$0 
Projections 
FY 2025-26 
($180,000) 
$0 
($180,000) 
$0 
Projections 
FY 2026-27 
($180,000) 
s:n 
($180,000) 
$0 
This amendment adds language stating the Legislature's finding that the requirements for coverage of blood testing for 
PF AS are not an addition to the State's essential health benefits that would require the State to defray costs pursuant to 
the federal Patient Protection and Affordable Care Act. Assuming this is a valid argument, the General Fund 
appropriations to the Department of Administrative and Financial Services of $90,000 for the estimated cost to 
reimburse insurance carriers for 6 months of the State's defrayal cost of this new mandate are removed. 
If this argument is deemed invalid in the future, there could potentially be up to $180,000 annual unfunded costs in the 
program in future biennia. 
LR0143(04) - Fiscal Note - Page I of I